WallStreetZenWallStreetZen

NASDAQ: BCDA
Biocardia Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for BCDA

Based on 1 analyst offering 12 month price targets for Biocardia Inc

Min Forecast
$25.00+3,142.54%
Avg Forecast
$25.00+3,142.54%
Max Forecast
$25.00+3,142.54%

Should I buy or sell BCDA stock?

Based on 1 analyst offering ratings for Biocardia Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although BCDA's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates BCDA as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -6.47% per year. Learn More

Be the first to know when Wall Street analysts revise their BCDA stock forecasts and price targets.

BCDA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-06-09

1 of 1

Forecast return on equity

Is BCDA forecast to generate an efficient return?

Forecast return on assets

Is BCDA forecast to generate an efficient return on assets?

Company
-277.86%
Industry
-7.18%
BCDA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BCDA earnings per share forecast

What is BCDA's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$0.69
Avg 2 year Forecast
-$0.54
Avg 3 year Forecast
-$0.42

BCDA revenue forecast

What is BCDA's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$4.2M

BCDA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BCDA$0.77$25.00+3,142.54%Buy
ASBP$6.72N/AN/A
IMRN$1.11N/AN/A
LNAI$2.02N/AN/A
NIKI$10.17N/AN/A
View Top Biotech Stocks

Biocardia Stock Forecast FAQ

Is Biocardia Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: BCDA) stock is to Buy BCDA stock.

Out of 1 analyst, 0 (0%) are recommending BCDA as a Strong Buy, 1 (100%) are recommending BCDA as a Buy, 0 (0%) are recommending BCDA as a Hold, 0 (0%) are recommending BCDA as a Sell, and 0 (0%) are recommending BCDA as a Strong Sell.

If you're new to stock investing, here's how to buy Biocardia stock.

What is BCDA's earnings growth forecast for 2026-2028?

(NASDAQ: BCDA) Biocardia's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 25.41%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 69.59%.

Biocardia's earnings in 2026 is -$7,775,000.On average, 4 Wall Street analysts forecast BCDA's earnings for 2026 to be -$7,889,509, with the lowest BCDA earnings forecast at -$8,471,894, and the highest BCDA earnings forecast at -$7,166,076. On average, 4 Wall Street analysts forecast BCDA's earnings for 2027 to be -$6,091,165, with the lowest BCDA earnings forecast at -$6,688,338, and the highest BCDA earnings forecast at -$5,374,557.

In 2028, BCDA is forecast to generate -$4,756,910 in earnings, with the lowest earnings forecast at -$4,681,836 and the highest earnings forecast at -$4,777,384.

What is BCDA's revenue growth forecast for 2026-2028?

(NASDAQ: BCDA) Biocardia's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 48.33%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 15.94%.

Biocardia's revenue in 2026 is $0.On average, 4 Wall Street analysts forecast BCDA's revenue for 2026 to be $0, with the lowest BCDA revenue forecast at $0, and the highest BCDA revenue forecast at $0. On average, 4 Wall Street analysts forecast BCDA's revenue for 2027 to be $0, with the lowest BCDA revenue forecast at $0, and the highest BCDA revenue forecast at $0.

In 2028, BCDA is forecast to generate $48,149,207 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $99,130,720.

What is BCDA's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: BCDA) forecast ROA is -277.86%, which is lower than the forecast US Biotechnology industry average of -7.18%.

What is BCDA's Price Target?

According to 1 Wall Street analyst that have issued a 1 year BCDA price target, the average BCDA price target is $25.00, with the highest BCDA stock price forecast at $25.00 and the lowest BCDA stock price forecast at $25.00.

The Wall Street analyst predicted that Biocardia's share price could reach $25.00 by Jun 9, 2027. The average Biocardia stock price prediction forecasts a potential upside of 3,142.54% from the current BCDA share price of $0.77.

What is BCDA's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: BCDA) Biocardia's current Earnings Per Share (EPS) is -$0.91. On average, analysts forecast that BCDA's EPS will be -$0.69 for 2026, with the lowest EPS forecast at -$0.74, and the highest EPS forecast at -$0.63. On average, analysts forecast that BCDA's EPS will be -$0.54 for 2027, with the lowest EPS forecast at -$0.59, and the highest EPS forecast at -$0.47. In 2028, BCDA's EPS is forecast to hit -$0.42 (min: -$0.41, max: -$0.42).

What is BCDA's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: BCDA) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.